Papaverine - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Spasmolytic agent, has antihypertensive effect. Inhibits phosphodiesterase, causes accumulation in the cell of cyclic adenosine monophosphate and a decrease in the content of calcium ions; reduces tone and relaxes the smooth muscles of internal organs (gastrointestinal tract, respiratory and genitourinary system) and vessels. In large doses reduces the excitability of the heart muscle and slows intracardiac conduction. The effect on the central nervous system is poorly expressed (in large doses a sedative effect is exerted).

Pharmacokinetics:

Absorption depends on the dosage form. Bioavailability on average - 54%.Connection with plasma proteins - 90 %. Well distributed, penetrates through the histo-hematical barriers. Metabolised in the liver. The half-life of the drug is 0.5-2 hours (it may extend up to 24 hours). It is excreted by the kidneys in the form of metabolites. Completely removed from the blood during hemodialysis.

Indications:

Spasm of smooth muscles: abdominal cavity organs (cholecystitis, pilorospasm, spastic colitis, renal colic); peripheral vessels (endarteritis); vessels of the brain; heart - angina (as part of complex therapy); bronchospasm.

As an auxiliary medicine for premedication.

Contraindications:

Hypersensitivity, AV blockade, glaucoma, severe hepatic insufficiency, elderly age (risk of hyperthermia development), children's age (up to 6 months).

Carefully:Conditions after traumatic brain injury, chronic renal failure, insufficiency of adrenal function, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, shock states.

Pregnancy and lactation:In pregnancy and lactation, the safety of the drug is not established.

Dosing and Administration:

Subcutaneously, intramuscularly - 1-2 ml of a solution with a concentration of 20 mg / ml (20-40 mg) 2-4 times a day; intravenously slowly - 20 mg with preliminary dilution in 10-20 ml 0,9 % solution of sodium chloride.

Side effects:Allergic reactions; AV blockade, ventricular extrasystole, lowering of arterial pressure (BP), constipation, drowsiness, increased activity of "liver" transaminases, eosinophilia.

Overdose:

Symptoms: diplopia, weakness, decreased blood pressure, drowsiness.

Treatment: symptomatic (maintenance of blood pressure).

Interaction:

Papaverin reduces the antiparkinsonian effect of levodopa and the hypotensive effect of methyldopa.

In combination with barbiturates, the spasmolytic effect of papaverine is enhanced.

When combined with tricyclic antidepressants, prokinainamide, reserpine, quinidine, the hypotensive effect of papaverine may increase.

Special instructions:

Intravenous should be administered slowly, under the supervision of a doctor.

During the treatment period, ethanol intake should be excluded.

In pregnancy and lactation, the safety of the drug is not established.

The vasodilating effect is reduced by smoking.

Form release / dosage:

Solution for injection 20 mg / ml.

Packaging:

2 ml into neutral glass ampoules.

5 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.

1 or 2 contour squares are placed in a pack of cardboard for consumer containers.

5, 10 ampoules are placed in a pack of cardboard for consumer containers with partitions or gratings, or a cardboard separator for consumer containers.

10 ampoules are placed in a box of cardboard for consumer containers.

Each instruction pack or box is supplied with instructions for use, an ampoule knife or ampoule scarifier.

In the case of using ampoules with incisions, dots or rings of a fracture, the ampoule knife or ampoule scaper is not inserted.

Storage conditions:

In a place protected from light and inaccessible to children at a temperature of no higher than 25 ° C.

Shelf life:

2 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LS-001523

Date of registration:15.12.2011

The owner of the registration certificate:BIOCHEMIST, OJSC BIOCHEMIST, OJSC Russia

Manufacturer: & nbsp

BIOCHEMIST, OJSC Russia

Information update date: & nbsp21.08.2015

Illustrated instructions

Instructions

Papaverine (Papaverine)